Literature DB >> 10805364

Association between HIV in pregnancy and antiretroviral therapy, including protease inhibitors and low birth weight infants.

P J Goldstein1, R Smit, M Stevens, J L Sever.   

Abstract

OBJECTIVE: To determine the incidence of low birth weight infants born to HIV seropositive women and to demonstrate any effects of antiretroviral therapy on birth weight.
METHODS: Retrospective review of all obstetrical medical records from January 1, 1995 through June 30, 1998 to identify HIV seropositive women. We evaluated their antiretroviral therapy, CD4 counts, and birth weights of their newborns. We conducted detailed review of the clinical and laboratory findings for the HIV-infected untreated patients, women who received ZDV antepartum alone, and those who received PIs as part of antiretroviral treatment.
RESULTS: The frequency of low birth weight infants was significantly increased in HIV seropositive compared to HIV seronegative parturients. Low birth weight infants were more frequent among HIV infected women with lower CD4 counts but the association was not statistically significant. Women who received no antepartum treatment, antepartum only ZDV, and those treated with PIs had significantly more low birth weight infants than did comparison groups. HIV seropositive women also had high frequencies of several obstetrical risk factors for low birth weight infants.
CONCLUSION: The present study showed a significantly increased frequency of low birth weight infants among HIV infected women and especially the subgroups of infected women who received no antepartum treatment, antepartum ZDV only, and those treated with PIs. This association, however, may be related to the presence of many other preterm obstetrical risk factors noted in this study. Increasing numbers of HIV seropositive women are being treated with PIs according to the Centers for Disease Control (CDC) guidelines. If PIs are a cause of low birth weight infants, women taking these drugs may have incremental risk of low birth weight.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805364      PMCID: PMC1784673          DOI: 10.1002/(SICI)1098-0997(2000)8:2<94::AID-IDOG6>3.0.CO;2-V

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  10 in total

Review 1.  The effect of HIV infection on pregnancy outcome.

Authors:  F D Johnstone
Journal:  Baillieres Clin Obstet Gynaecol       Date:  1992-03

2.  Impact of maternal HIV infection on obstetrical and early neonatal outcome.

Authors:  M R Braddick; J K Kreiss; J B Embree; P Datta; J O Ndinya-Achola; H Pamba; G Maitha; P L Roberts; T C Quinn; K K Holmes
Journal:  AIDS       Date:  1990-10       Impact factor: 4.177

3.  Progestogen administration in pregnancy may prevent preterm delivery.

Authors:  M J Keirse
Journal:  Br J Obstet Gynaecol       Date:  1990-02

Review 4.  HIV-protease inhibitors.

Authors:  C Flexner
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

5.  Annual summary of vital statistics--1996.

Authors:  B Guyer; J A Martin; M F MacDorman; R N Anderson; D M Strobino
Journal:  Pediatrics       Date:  1997-12       Impact factor: 7.124

6.  Association of maternal HIV infection with low birth weight.

Authors:  L E Markson; B J Turner; R Houchens; N S Silverman; L Cosler; B K Takyi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-11-01

Review 7.  Human immunodeficiency virus infection in pregnancy.

Authors:  S N MacGregor
Journal:  Clin Perinatol       Date:  1991-03       Impact factor: 3.430

8.  The effect of human immunodeficiency virus infection and drug use on birth characteristics.

Authors:  F D Johnstone; G M Raab; B A Hamilton
Journal:  Obstet Gynecol       Date:  1996-09       Impact factor: 7.661

9.  Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. New York City Perinatal HIV Transmission Collaborative Study Group.

Authors:  L Kuhn; E J Abrams; P B Matheson; P A Thomas; G Lambert; M Bamji; B Greenberg; R W Steketee; D M Thea
Journal:  AIDS       Date:  1997-03-15       Impact factor: 4.177

10.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

  10 in total
  6 in total

Review 1.  Role of the placenta in adverse perinatal outcomes among HIV-1 seropositive women.

Authors:  William Ackerman; Jesse J Kwiek
Journal:  J Nippon Med Sch       Date:  2013       Impact factor: 0.920

2.  Expression of regulatory T cell (Treg) activation markers in endometrial tissues from early and late pregnancy in the feline immunodeficiency virus (FIV)-infected cat.

Authors:  N N Lockett; V L Scott; C E Boudreaux; B T Clay; S B Pruett; P L Ryan; K S Coats
Journal:  Placenta       Date:  2010-08-02       Impact factor: 3.481

Review 3.  Placental immunopathology in the FIV-infected cat: a role for inflammation in compromised pregnancy?

Authors:  Karen S Coats; Crystal E Boudreaux; Brittany T Clay; Nikki N Lockett; Veronica L Scott
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

4.  Impact of maternal HIV infection on pregnancy outcomes in southwestern China - a hospital registry based study.

Authors:  M Yang; Y Wang; Y Chen; Y Zhou; Q Jiang
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

5.  Aberrant placental immune parameters in the feline immunodeficiency virus (FIV)-infected cat suggest virus-induced changes in T cell function.

Authors:  Lyndon Bart Chumbley; Crystal E Boudreaux; Karen S Coats
Journal:  Virol J       Date:  2013-07-19       Impact factor: 4.099

Review 6.  Antiviral and antiretroviral use in pregnancy.

Authors:  Deborah M Money
Journal:  Obstet Gynecol Clin North Am       Date:  2003-12       Impact factor: 2.844

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.